Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone

J Clin Pharmacol. 2011 Feb;51(2):271-8. doi: 10.1177/0091270010365558. Epub 2010 Apr 26.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / pharmacokinetics
  • Buprenorphine / administration & dosage
  • Buprenorphine / adverse effects
  • Buprenorphine / pharmacokinetics*
  • Darunavir
  • Drug Interactions
  • Female
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / pharmacology
  • Humans
  • Male
  • Methadone / adverse effects
  • Methadone / pharmacokinetics*
  • Middle Aged
  • Naloxone / administration & dosage
  • Naloxone / adverse effects
  • Naloxone / pharmacokinetics*
  • Narcotic Antagonists / administration & dosage
  • Narcotic Antagonists / adverse effects
  • Narcotic Antagonists / pharmacokinetics
  • Opiate Substitution Treatment / methods
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects
  • Ritonavir / pharmacology*
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology*

Substances

  • Analgesics, Opioid
  • HIV Protease Inhibitors
  • Narcotic Antagonists
  • Sulfonamides
  • Naloxone
  • Buprenorphine
  • Ritonavir
  • Methadone
  • Darunavir